Biotech News
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
ir.newamsterdampharma.com2026-05-07 11:06 EST
– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with